Clinical Trials Logo

Clinical Trial Summary

Primary open-angle glaucoma (POAG) is a chronic eye disease in which the only validated treatment is to lower intraocular pressure (IOP). It is the 2nd leading cause of blindness worldwide. The iStent® inject and inject W is an implantable device that is part of a new entity of so-called minimally invasive glaucoma surgery whose goal is to lower IOP with minimal tissue disruption in order to avoid the complications of conventional glaucoma surgery. This surgery is used in conjunction with cataract surgery in France. The primary objective is to study the 1-year efficacy and safety of combined cataract and iStent inject and inject W in the management of POAG in an observational, retrospective, controlled study of a cohort of POAG patients undergoing cataract surgery only.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05062668
Study type Observational
Source Centre Hospitalier Universitaire, Amiens
Contact Benjamin Jany, MD
Phone 03 22 08 92 19
Email [email protected]
Status Recruiting
Phase
Start date October 8, 2021
Completion date March 2022

See also
  Status Clinical Trial Phase
Recruiting NCT02792803 - A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma Phase 4
Recruiting NCT02312362 - High Frequency Deep Sclerotomy (HFDS) ab Interno a Combination Surgical Intervention Using Cataract Surgery to Lower IOP N/A